Cerebrolysin
Peptide ·Exploratory record · not publication-reviewed ·Updated July 13, 2026
Cerebrolysin is a porcine-derived peptide mixture with neurotrophic-like activity, used in some countries for stroke, dementia, and traumatic brain injury. It is not FDA-approved in the United States. Meta-analyses and Cochrane reviews show mixed or uncertain clinical benefit, so import or wellness use should be avoided.
Exploratory record, not a reviewed medical publication.
See the editorial and medical-review policies for the publication gate.
This safety record covers a controlled, investigational, or otherwise out-of-scope substance. It remains available for reference, but it is not part of NutriStack's public supplement publication set.
What the research says.
A quick, data-only summary. The full evidence, dosing, and sources are below.
Cerebrolysin is a peptide most often used for studied for acute ischemic stroke recovery, studied for vascular dementia and alzheimer disease, neurotrophic-like preclinical activity. NutriStack rates the overall evidence as emerging. A typical adult dose is No FDA-approved US dose; international trials often used 10-50 mL IV daily for 10-21 days depending indication, commonly taken as regulated injectable product only where approved; avoid import or research use. This profile indexes 3 sources.
- Dizziness
- Headache
- Agitation
- Severe renal impairment unless specialist-approved
- Epilepsy or uncontrolled seizures without neurologist review
The bottom line
Evidence rating emerging. Most-documented uses: studied for acute ischemic stroke recovery, studied for vascular dementia and alzheimer disease, neurotrophic-like preclinical activity. 3 sources indexed (2017–2023), with 0 interaction records on file.
How it works, mechanistically.
Core mechanism
Cerebrolysin contains low-molecular-weight peptides and amino acids proposed to mimic neurotrophic effects, reduce excitotoxicity, support synaptic plasticity, and modulate apoptosis in neural injury models. Clinical effects vary by indication and trial design. Because it is an injectable animal-derived biologic mixture, quality, hypersensitivity, and infection-control standards matter.1,2
Dosing & protocol.
Peptides are generally not reliably orally bioavailable unless a specific studied oral formulation is used. Human use of research-grade products is not appropriate.
What it actually costs.
Real-world pricing across three quality tiers. Assumes Regulated Injectable Cerebrolysin.
Research-market pricing is not a dosing recommendation; human use is not FDA-approved unless specifically stated. Updated 2026-06-04.
Full safety detail.
Side effects
- Dizziness
- Headache
- Agitation
- Sweating
- Nausea
- Injection or infusion reactions
- Hypersensitivity reaction
Contraindications
- Severe renal impairment unless specialist-approved
- Epilepsy or uncontrolled seizures without neurologist review
- Allergy to porcine-derived products
- Pregnancy and breastfeeding unless specialist-directed
- Use of unregulated imported injectable products
Sources, by evidence tier.
Numbered references. Citations throughout the page link here.
Meta-analyses & systematic reviews
3- 1Cerebrolysin for acute ischaemic strokeZiganshina LE et al. · Cochrane Database of Systematic Reviews · 2023
No clear all-cause mortality benefit
- 2Cerebrolysin for vascular dementiaCui S et al. · Cochrane Database of Systematic Reviews · 2019
Small trials suggested possible cognitive effects
- 3Efficacy and Safety of Cerebrolysin for Acute Ischemic Stroke: A Meta-Analysis of Randomized Controlled TrialsZhang L et al. · BioMed Research International · 2017
Efficacy outcomes were not consistently superior
Common questions.
Quick answers about Cerebrolysin, drawn from the data on this page.
What is Cerebrolysin?
Cerebrolysin is a porcine-derived peptide mixture with neurotrophic-like activity, used in some countries for stroke, dementia, and traumatic brain injury. It is not FDA-approved in the United States. Meta-analyses and Cochrane reviews show mixed or uncertain clinical benefit, so import or wellness use should be avoided.
What is Cerebrolysin used for?
Commonly cited benefits of Cerebrolysin include: Studied for acute ischemic stroke recovery; Studied for vascular dementia and Alzheimer disease; Neurotrophic-like preclinical activity; Not FDA-approved in the US. NutriStack rates the overall evidence as emerging.
What is a typical dose of Cerebrolysin?
A typical adult dose of Cerebrolysin is No FDA-approved US dose; international trials often used 10-50 mL IV daily for 10-21 days depending indication. The commonly recommended form is Regulated injectable product only where approved; avoid import or research use. These are general ranges, not personalized advice; confirm the right dose with a clinician.
What are the side effects of Cerebrolysin?
Reported side effects include dizziness, headache, agitation, sweating, nausea, injection or infusion reactions. This is educational information; check with a healthcare professional before use.
How strong is the evidence for Cerebrolysin?
NutriStack rates this as Emerging, meaning early RCT signal, mechanistic data, or limited human evidence. Full tier criteria are at https://nutristackapp.com/methodology/evidence-tiers.
Use this with your stack
Cerebrolysin in NutriStack.
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.